Profiling Resistance Development in SARS-CoV-2 After Nirmatrelvir-Remdesivir Treatment
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on October 16th, 2024
|
The antiviral combination of nirmatrelvir and remdesivir has played a crucial role in the fight against the COVID-19 pandemic. However, like all antimicrobials, random mutations and the selective pressure exerted by these treatments can lead to the emergence of SARS-CoV-2 variants resistant to nirmatrelvir and remdesivir. In response, the National Institutes of Health funded a study to investigate the development of resistance genotypes following treatment with this antiviral combination.
The prospective cohort study involved 156 patients diagnosed with acute COVID-19. Nasal swab sequencing revealed that about 10% of participants were infected with the BA.2 lineage of SARS-CoV-2, 30% with the BA.5 lineage, and another 30% with the XBB lineage. Based on physician discretion, 79 patients received the nirmatrelvir-remdesivir combination, while the remaining participants were treated with other medications. Resistance mutations were detected in 11.4% of those treated with nirmatrelvir-remdesivir, compared to 3.2% in the control group; however, this difference was not statistically significant. Resistance mutations were observed more frequently in immunocompromised patients, but these mutations occurred at low levels and could disappear randomly from the viral population. The study had some design limitations, such as a significantly higher median age and a higher frequency of immunocompromised individuals in the nirmatrelvir-remdesivir group compared to the control group. Despite these limitations, the study provides important insights into the development of treatment-resistant phenotypes in SARS-CoV-2, and future research with improved study design is needed to explore this phenomenon with other antiviral treatments.
The prospective cohort study involved 156 patients diagnosed with acute COVID-19. Nasal swab sequencing revealed that about 10% of participants were infected with the BA.2 lineage of SARS-CoV-2, 30% with the BA.5 lineage, and another 30% with the XBB lineage. Based on physician discretion, 79 patients received the nirmatrelvir-remdesivir combination, while the remaining participants were treated with other medications. Resistance mutations were detected in 11.4% of those treated with nirmatrelvir-remdesivir, compared to 3.2% in the control group; however, this difference was not statistically significant. Resistance mutations were observed more frequently in immunocompromised patients, but these mutations occurred at low levels and could disappear randomly from the viral population. The study had some design limitations, such as a significantly higher median age and a higher frequency of immunocompromised individuals in the nirmatrelvir-remdesivir group compared to the control group. Despite these limitations, the study provides important insights into the development of treatment-resistant phenotypes in SARS-CoV-2, and future research with improved study design is needed to explore this phenomenon with other antiviral treatments.